Diaminodiphenylsulphone (dapsone) has proved a safe and effective drug, since its introduction in the 1940s, in the management of a variety of conditions from leprosy and malarial prophylaxis to dermatitis herpetiformis. The toxic effects and adverse reactions to dapsone have been well documented. In the early years after the introduction of dapsone to clinical use hypersensitivity reactions to dapsone occurred frequently but then rapidly declined. Few cases were reported between the mid 1950s and the late 1970s. However, over the last 5 or 6 years case reports of hypersensitivity reactions to dapsone have reappeared in the literature. This paper reviews the literature on hypersensitivity reactions to dapsone and presents the findings of a postal survey carried out in 1986.
Literature review
A number of adverse reactions associated with dapsone have been reported sporadically including agranulocytosis, I peripheral neuropathies,2 toxic epidermal necrolysis,3 hypoalbuminaemia,4 phototoxicity,5 nephrotic syndrome,6 and haemolysis7• The toxic effects associated with dapsone in high dosage have also been well documented and these include renal impairment,8 haemolytic jaundice,9 hepatitis,1O methaemoglobinaemia, II psychosis,12 and optic atrophy. 13 The frequency of adverse reactions appears to be associated with dosage, and is higher when the dose is in excess of 100 mg daily. There have been a number of review articlesl4.15 on the side-effects of dapsone but the concensus remains that dapsone is an extremely safe drug.
Hypersensitivity reactions to sulphones were reportedl6 as early as 1944 when used to treat tuberculosis and laterl7 in the treatment ofleprosy. Many adverse reactions were encountered in the early use of the suI phones and attempts were made to find a less toxic derivative. 18 The earliest reports of a hypersensitivity reaction to dapsone was published in 1949 based on work in Nigeria. 19 In this early description of the reaction it was thought that dapsone precipitated glandular fe ver. The 'illness' arose early in the treatment and was characterized by fe ver, lymphadenitis, splenomegaly, jaundice, abnormal liver fu nction tests, mononucleosis, and dermatitis including generalized exfoliation. Positive Paul Bunnell tests and mononucleosis led to the diagnosis of glandular fe ver. The authors suggested a gradual build up in dose to 300 mg daily was advisable to avoid this complication.
Lowe reviewed the situation in 195020 when reporting 3 fu rther cases of hypersensitivity reaction and advised early withdrawal of dapsone, the use of antihistamines fo llowed by desensitization. Another publication reported liver biopsy evidence of hepatic damage in 3 cases ofthe reaction. 21 In 1951 the reported frequency of hypersensitivity to dapsone was 2%,22 fatal outcomes associated with exfoliation were reported and the relation between the reaction and doses in excess of 100 mg daily noted. In 1957 Barnes coined the name dapsone syndrome23 and advised lowering the dose of dapsone.24 Other workers reported an incidence of hypersensitivity to dapsone when used on a mass scale.25.26 Case reports appeared from Malaya27 and New Guinea. 28 From 1956 until 1980 there were only 2 reports of the reaction in the literature. A number of papers were published on the management of the reaction; the use of cortisone in sensItivIty reactions29 and methods of desensitization;30 but the only case reports of hypersensitivity reactions to dapsone were in 196731 and in 1970.32 There are other reports in the literature, during this 24-year period, of jaundice associated with dapsone but they do not have the other diagnostic fe atures of hypersensitivity and are mostly haemolytic. Then from 1980 to the present there were 27 case reports published (Table 1 ). The published case reports of hypersensitivity reactions to dapsone between 1949 and the present have been plotted (Figure 1 ). The characteristics of the most recent 27 cases of hypersensitivity reaction were that 9 were in men and 14 in women (4 the sex was not reported) in the age range 7-50 years. Twenty-two were in leprosy patients, 2 in the treatment of dermatitis herpetiformis and one each in the treatment of acne vulgaris, psoriasis and vascM f tis. In 23 out of the 27 the dose of dapsone was specified; 16 were on dapsone alone and the remainder were taking dapsone as part of the multidrug regimen (Table 1) .
Postal survey
In order to estimate whether these reported cases represented all cases occurring and to estimate the frequency of occurrence of hypersensitivity a postal survey was undertaken. Leprosy centres were chosen as they were likely to be treating large numbers of new cases with dapsone. Since the syndrome occurs within 6 weeks of commencement of dapsone therapy only new cases were of interest. A total of 73 centres were included covering Asia, South and Central America and Africa and replies were received from one-third. Many centres did not treat many new cases and were thus unlikely to encounter the reaction.
Five of the 26 centres replying had recently encountered cases of hypersensitivity and provided case histories of at least 10 episodes (Table 2 ). These centres were in Nigeria, Korea, India, Zambia and Thailand. Four of the cases were receiving multidrug therapy with c10fazimine and rifampicin along with dapsone. Two were from previous years and associated with dapsone alone. One centre although admitting to experiencing cases did not provide clinical details. It was not possible to give an overall estimate of the frequency of the dapsone syndrome but it varied from 0 to 2% of new cases treated.
Discussion
Review of the literature on case reports of hypersensitivity reactions to dapsone shows the reaction to be common (2-12%) in the early years after the introduction of dapsone to clinical use, and then to virtually disappear from the literature between 1956 and 1980. The reasons fo r this seem unclear and no serious attempt has been made to explain the apparent disappearance. Three distinct explanations seem possible: firstly, the reaction has continued to occur but has not been recognized; secondly, the reaction has continued to occur, has been recognized but has not been reported, and finally, the reaction in fact virtually disappeared over this period. The first explanation seems unlikely due to its severity, while the second is possible having discussed the problem with many mass users of dapsone, although the sudden reappearance of case reports from 1980 onwards describe the hypersensitivity reaction as an unusual occurrence. One conclusion from these arguments is that hypersensitivity reactions to dapsone did virtually disappear between 1956 and 1980. A proposed explanation is that the incidence of the reaction is related to dose;35 in the 1950s the recommended dose of dapsone was reduced from 300 mg to 100 mg daily. However, it has been argued that hypersensitivity reactions to dapsone36 or to any other drug50 are not dose dependent. Explanations on the genetic basis of hypersensitivity reactions cannot explain sudden changes; and changes in manufacture of dapsone have not been investigated.
The sudden reappearance of reports of the hypersensitivity reaction to dapsone since 1980 also needs to be considered. Publication bias may be a possibility but from the results of the postal survey support the fact that the syndrome is occurring widely. There has been no major increase in the use of dapsone recently but since 198251 multidrug regimens, including dapsone, have been recommended in the treatment ofleprosy. It is possible that these more complex multidrug regimens lead to wrong administration of dapsone, there is also the potential for drug interactions. About half of the recent cases of hypersensitivity since 1980 have been associated with dapsone monotherapy which does not support a drug interaction therapy as a complete explanation. There have been well-documented cases of hypersensitivity reactions with similar characteristics associated with cIofazimine52 and rifampicin,53 this may well appear to exaggerate the frequency of hypersensitivity to dapsone. One other consideration is that dapsone is prepared in combination with pyrimethamine for malarial prophylaxis and may be dispensed in this form instead of dapsone alone,54 adverse reactions in these circumstances may therefore not necessarily be to dapsone.
